January 2027 Options Now Available For Amylyx Pharmaceuticals (AMLX)

The piece presents option trade ideas on Amylyx Pharmaceuticals (AMLX) around the $15 put (bid $4.20) and the $17 call (bid $5.00) with the stock at $16.60. Selling the $15 put nets a $10.80 effective cost basis and is shown as having a 77% chance to expire worthless, producing a 28.00% return (28.47% annualized); selling a covered $17 call from current stock ownership would generate a 32.53% total return to Jan 2027 with a 28% chance to expire worthless and a 30.12% YieldBoost (30.62% annualized). Implied volatilities are high (put 128%, call 114%) versus trailing 12-month volatility of 73%, and Stock Options Channel will track odds and contract histories on its site.

Analysis

Contrarian angles: Consensus underestimates the value of selling premium given IV vs realized spread, but many underestimate binary downside — selling naked puts without hedges is crowded and could be painful on a negative trigger. The market may be underpricing the probability of dilution; if management signals additional capital raises, option yields can evaporate and shares can gap lower. Historical parallel: mid‑cap therapeutics often offer short‑term premium sellers 20–40% annualized returns until a binary event; the key risk is idiosyncratic binary outcomes rather than structural mispricing, so enforce strict size and protective hedges.

Key Decisions for Investors

• Sell cash‑secured AMLX Jan‑2027 $15 puts (collect $4.20) sized to target ≤2% of portfolio notional; set hard max loss if assigned and price falls below $12 — OR buy a protective $8–$10 long put to cap downside; roll or close if IV falls below 90% or within 30 days of a confirmed negative catalyst.
• Establish a 1–2% long position in AMLX stock at current ~$16.60 and sell the Jan‑2027 $17 covered call (collect ~$5) to generate ~32% gross return if called; use a protective collar (buy Jan‑2027 $12 put) if unwilling to risk >25% downside.
• Implement a relative‑value hedge: pair the AMLX long/put‑sell exposure with a 0.5–1.0% short in XBI (or IBB) to neutralize sector beta; adjust hedge ratio if XBI outperforms by >8% over a 30‑day rolling window.
• Avoid naked short premium >3% NAV and do not add exposure prior to FDA/clinical readouts or any S‑3 filing; monitor SEC filings and FDA calendar daily for 30–90 day horizon — if an S‑3 or unfavorable FDA interaction appears, close option sells and reduce net exposure to zero.